Ascendis Pharma to Initiate TransCon PTH U.S. Expanded Access Program for Adult Patients with Hypoparathyroidism
05.12.2022 - - The program will allow physicians to request access to TransCon PTH, the company’s investigational parathyroid hormone replacement therapy, for eligible patients in the United States - TransCon PTH is under Priority Review by the FDA, with a ... Seite 1